Hematologists, oncologists Multiple myeloma is the second most common hematologic malignancy, affecting 14,000 patients per year in the United States. Despite the advent of high-dose chemotherapy with stem cell transplantation, multiple myeloma remains incurable, causing approximately 12,000 deaths per annum in the US. Over the last 10 years, there has been a dramatic increase in our understanding of the biology of multiple myeloma, which has provided insights into mechanisms of cytotoxic resistance, both as inherent characteristics of the myeloma cell and the protective interaction between the tumor and its bone marrow microenvironment, Moreover, advances in our understanding of multiple myeloma pathogenesis have helped further define the intricacies of this complex disease. Through this greater understanding, a large array of new therapies has been engendered and a significant impact is being made on patient outcome as a result. This book provides a concise overview of the state of the art in multiple myeloma and should be of primary interest to clinicians, scientists, and related caregivers alike in this rapidly changing field.Anderson, Ken is the author of 'Multiple Myeloma' with ISBN 9781901346480 and ISBN 190134648X.